Shots:

• The P-III (LUCENT-2) maintenance study evaluates mirikizumab vs PBO in patients with UC. The results are based on the (LUCENT-1) study
• The trial met its 1EPs & 2EPs i.e., patients treated with mirikizumab achieved clinical response @1yrs. and were re-randomized to maintenance dosing, higher proportions of patients treated with mirikizumab showed an improvement in corticosteroid-free remission, clinical, endoscopic, histologic measures & reduction of bowel urgency @1yrs. The safety profile was consistent with previous mirikizumab studies & other studies within the anti-IL-23p19 Ab
• The company plans to submit a BLA to the US FDA and the regulatory agencies globally for mirikizumab in UC in H1’22

Ref: Lilly | Image: Eli Lilly